Criteria, prevalence, and phenotypes of polycystic ovary syndrome

Fertility and Sterility

Volumn 106, Issue 1, 2016, Pages 6-15

  Lizneva, Daria ^a,b,c   Suturina, Larisa ^c   Walker, Walidah ^a   Brakta, Soumia ^a   Gavrilova Jordan, Larisa ^a   Azziz, Ricardo ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b Mother and Child Clinic IDK Medical Company   (Russian Federation)

^c SCIENTIFIC CENTRE FOR FAMILY HEALTH AND HUMAN REPRODUCTION PROBLEMS   (Russian Federation)

Author keywords

Phenotypes; polycystic ovary syndrome; prevalence; referral bias

Indexed keywords

ANDROGEN;

ADOLESCENT; CLIMACTERIUM; CLINICAL FEATURE; DISEASE CLASSIFICATION; ETHNICITY; HORMONE BLOOD LEVEL; HUMAN; MENSTRUATION DISORDER; MORBIDITY; OVARY POLYCYSTIC DISEASE; OVULATION; PATIENT REFERRAL; PHENOTYPE; POPULATION; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; REVIEW; ADULT; AGE DISTRIBUTION; CLASSIFICATION; FEMALE; ONSET AGE; PATHOPHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; PREDICTIVE VALUE; REPRODUCTION; REPRODUCTIVE HEALTH; RISK FACTOR; SELECTION BIAS; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE OF ONSET; FEMALE; HUMANS; PHENOTYPE; POLYCYSTIC OVARY SYNDROME; PREDICTIVE VALUE OF TESTS; PREVALENCE; REFERRAL AND CONSULTATION; REPRODUCTION; REPRODUCTIVE HEALTH; RISK FACTORS; SELECTION BIAS; YOUNG ADULT;

EID: 84973539382     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2016.05.003     Document Type: Review

References (101)

1. 1 Azziz, R., Woods, K.S., Reyna, R., Key, T.J., Knochenhauer, E.S., Yildiz, B.O., The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89 (2004), 2745–2749.
2. 2 Yildiz, B.O., Bozdag, G., Yapici, Z., Esinler, I., Yarali, H., Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 27 (2012), 3067–3073.
3. 3 Puurunen, J., Piltonen, T., Morin-Papunen, L., Perheentupa, A., Jarvela, I., Ruokonen, A., et al. Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. J Clin Endocrinol Metab 96 (2011), 1827–1834.
4. 4 Shaw, L.J., Bairey Merz, C.N., Azziz, R., Stanczyk, F.Z., Sopko, G., Braunstein, G.D., et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health–National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 93 (2008), 1276–1284.
5. 5 Diamanti-Kandarakis, E., Dunaif, A., Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33 (2012), 981–1030.
6. 6 Ferriman, D., Purdie, A.W., The aetiology of oligomenorrhoea and/or hirsuties: a study of 467 patients. Postgrad Med J 59 (1983), 17–20.
7. 7 Balen, A.H., Conway, G.S., Kaltsas, G., Techatrasak, K., Manning, P.J., West, C., et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 10 (1995), 2107–2111.
8. 8 DeUgarte, C.M., Bartolucci, A.A., Azziz, R., Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 83 (2005), 1454–1460.
9. 9 Norman, R.J., Masters, L., Milner, C.R., Wang, J.X., Davies, M.J., Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 16 (2001), 1995–1998.
10. 10 Krentz, A.J., von Muhlen, D., Barrett-Connor, E., Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease. Menopause 14 (2007), 284–292.
11. 11 Legro, R.S., Kunselman, A.R., Dunaif, A., Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 111 (2001), 607–613.
12. 12 Wild, S., Pierpoint, T., McKeigue, P., Jacobs, H., Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 52 (2000), 595–600.
13. 13 Jedel, E., Waern, M., Gustafson, D., Landen, M., Eriksson, E., Holm, G., et al. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Hum Reprod 25 (2010), 450–456.
14. 14 Boomsma, C.M., Eijkemans, M.J., Hughes, E.G., Visser, G.H., Fauser, B.C., Macklon, N.S., A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 12 (2006), 673–683.
15. 15 Qin, J.Z., Pang, L.H., Li, M.J., Fan, X.J., Huang, R.D., Chen, H.Y., Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol, 11, 2013, 56.
16. 16 Kjerulff, L.E., Sanchez-Ramos, L., Duffy, D., Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis. Am J Obstet Gynecol 204 (2011), 558.e1–558.e6.
17. 17 Hart, R., Doherty, D.A., The potential implications of a PCOS diagnosis on a woman's long-term health using data linkage. J Clin Endocrinol Metab 100 (2015), 911–919.
18. 18 Zawadzki, J.K., Dunaif, A., Diagnostic criteria for polycystic ovary syndrome; towards a rational approach. Dunaif, A., Givens, J.R., Haseltine, F., Merriam, G., (eds.) Polycystic ovary syndrome, 1992, Blackwell Scientific, Boston.
19. 19 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004), 19–25.
20. 20 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19 (2004), 41–47.
21. 21 Azziz, R., Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 91 (2006), 781–785.
22. 22 Franks, S., Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab 91 (2006), 786–789.
23. 23 National Institutes of Health. Evidence-based methodology workshop on polycystic ovary syndrome, December 3-5, 2012. Executive summary. Available at: https://prevention.nih.gov/docs/programs/pcos/FinalReport.pdf. Accessed March 1, 2016.
24. 24 Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H.F., Futterweit, W., et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91 (2006), 4237–4245.
25. 25 Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H.F., Futterweit, W., et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91 (2009), 456–488.
26. 26 Broekmans, F.J., Knauff, E.A., Valkenburg, O., Laven, J.S., Eijkemans, M.J., Fauser, B.C., PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG 113 (2006), 1210–1217.
27. 27 Rosencrantz, M.A., Coffler, M.S., Haggan, A., Duke, K.B., Donohue, M.C., Shayya, R.F., et al. Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome. J Clin Endocrinol Metab 96 (2011), 1106–1113.
28. 28 Georgopoulos, N.A., Papadakis, E., Armeni, A.K., Katsikis, I., Roupas, N.D., Panidis, D., Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS). Hormones (Athens) 13 (2014), 213–221.
29. 29 Carmina, E., Chu, M.C., Longo, R.A., Rini, G.B., Lobo, R.A., Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 90 (2005), 2545–2549.
30. 30 Legro, R.S., Arslanian, S.A., Ehrmann, D.A., Hoeger, K.M., Murad, M.H., Pasquali, R., et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 98 (2013), 4565–4592.
31. 31 Bridges, N.A., Cooke, A., Healy, M.J., Hindmarsh, P.C., Brook, C.G., Standards for ovarian volume in childhood and puberty. Fertil Steril 60 (1993), 456–460.
32. 32 Fruzzetti, F., Campagna, A.M., Perini, D., Carmina, E., Ovarian volume in normal and hyperandrogenic adolescent women. Fertil Steril 104 (2015), 196–199.
33. 33 Rosenfield, R.L., Ghai, K., Ehrmann, D.A., Barnes, R.B., Diagnosis of the polycystic ovary syndrome in adolescence: comparison of adolescent and adult hyperandrogenism. J Pediatr Endocrinol Metab 13:Suppl 5 (2000), 1285–1289.
34. 34 Glueck, C.J., Woo, J.G., Khoury, P.R., Morrison, J.A., Daniels, S.R., Wang, P., Adolescent oligomenorrhea (age 14-19) tracks into the third decade of life (age 20-28) and predicts increased cardiovascular risk factors and metabolic syndrome. Metabolism 64 (2015), 539–553.
35. 35 Rosenfield, R.L., The diagnosis of polycystic ovary syndrome in adolescents. Pediatrics 136 (2015), 1154–1165.
36. 36 Salameh, W.A., Redor-Goldman, M.M., Clarke, N.J., Reitz, R.E., Caulfield, M.P., Validation of a total testosterone assay using high-turbulence liquid chromatography tandem mass spectrometry: total and free testosterone reference ranges. Steroids 75 (2010), 169–175.
37. 37 DeUgarte, C.M., Woods, K.S., Bartolucci, A.A., Azziz, R., Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J Clin Endocrinol Metab 91 (2006), 1345–1350.
38. 38 Fauser, B.C., Tarlatzis, B.C., Rebar, R.W., Legro, R.S., Balen, A.H., Lobo, R., et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 97 (2012), 28–38.e25.
39. 39 Elting, M.W., Korsen, T.J., Rekers-Mombarg, L.T., Schoemaker, J., Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 15 (2000), 24–28.
40. 40 Elting, M.W., Kwee, J., Korsen, T.J., Rekers-Mombarg, L.T., Schoemaker, J., Aging women with polycystic ovary syndrome who achieve regular menstrual cycles have a smaller follicle cohort than those who continue to have irregular cycles. Fertil Steril 79 (2003), 1154–1160.
41. 41 Alsamarai, S., Adams, J.M., Murphy, M.K., Post, M.D., Hayden, D.L., Hall, J.E., et al. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J Clin Endocrinol Metab 94 (2009), 4961–4970.
42. 42 Pinola, P., Piltonen, T.T., Puurunen, J., Vanky, E., Sundstrom-Poromaa, I., Stener-Victorin, E., et al. Androgen profile through life in women with polycystic ovary syndrome: a Nordic multicenter collaboration study. J Clin Endocrinol Metab 100 (2015), 3400–3407.
43. 43 Rosner, W., Auchus, R.J., Azziz, R., Sluss, P.M., Raff, H., Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 92 (2007), 405–413.
44. 44 Knochenhauer, E.S., Key, T.J., Kahsar-Miller, M., Waggoner, W., Boots, L.R., Azziz, R., Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83 (1998), 3078–3082.
45. 45 March, W.A., Moore, V.M., Willson, K.J., Phillips, D.I., Norman, R.J., Davies, M.J., The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 25 (2010), 544–551.
46. 46 Boyle, J.A., Cunningham, J., O'Dea, K., Dunbar, T., Norman, R.J., Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia. Med J Aust 196 (2012), 62–66.
47. 47 Gabrielli, L., Aquino, E.M., Polycystic ovary syndrome in Salvador, Brazil: a prevalence study in primary healthcare. Reprod Biol Endocrinol, 10, 2012, 96.
48. 48 Chen, X., Yang, D., Mo, Y., Li, L., Chen, Y., Huang, Y., Prevalence of polycystic ovary syndrome in unselected women from southern China. Eur J Obstet Gynecol Reprod Biol 139 (2008), 59–64.
49. 49 Ma, Y.M., Li, R., Qiao, J., Zhang, X.W., Wang, S.Y., Zhang, Q.F., et al. Characteristics of abnormal menstrual cycle and polycystic ovary syndrome in community and hospital populations. Chin Med J (Engl) 123 (2010), 2185–2189.
50. 50 Li, R., Zhang, Q., Yang, D., Li, S., Lu, S., Wu, X., et al. Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod 28 (2013), 2562–2569.
51. 51 Zhang, H.Y., Zhu, F.F., Xiong, J., Shi, X.B., Fu, S.X., Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. BJOG 116 (2009), 1633–1639.
52. 52 Lauritsen, M.P., Bentzen, J.G., Pinborg, A., Loft, A., Forman, J.L., Thuesen, L.L., et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod 29 (2014), 791–801.
53. 53 Zhuang, J., Liu, Y., Xu, L., Liu, X., Zhou, L., Tang, L., et al. Prevalence of the polycystic ovary syndrome in female residents of Chengdu, China. Gynecol Obstet Invest 77 (2014), 217–223.
54. 54 Tehrani, F.R., Rashidi, H., Khomami, M.B., Tohidi, M., Azizi, F., The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran. Reprod Biol Endocrinol, 12, 2014, 89.
55. 55 Mehrabian, F., Khani, B., Kelishadi, R., Ghanbari, E., The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria. Endokrynol Pol 62 (2011), 238–242.
56. 56 Rashidi, H., Ramezani Tehrani, F., Bahri Khomami, M., Tohidi, M., Azizi, F., To what extent does the use of the Rotterdam criteria affect the prevalence of polycystic ovary syndrome? A community-based study from the Southwest of Iran. Eur J Obstet Gynecol Reprod Biol 174 (2014), 100–105.
57. 57 Sanchon, R., Gambineri, A., Alpanes, M., Martinez-Garcia, M.A., Pasquali, R., Escobar-Morreale, H.F., Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. Hum Reprod 27 (2012), 1209–1216.
58. 58 Moran, C., Tena, G., Moran, S., Ruiz, P., Reyna, R., Duque, X., Prevalence of polycystic ovary syndrome and related disorders in Mexican women. Gynecol Obstet Invest 69 (2010), 274–280.
59. 59 Musmar, S., Afaneh, A., Mo'alla, H., Epidemiology of polycystic ovary syndrome: a cross sectional study of university students at An-Najah national university-Palestine. Reprod Biol Endocrinol, 11, 2013, 47.
60. 60 Asuncion, M., Calvo, R.M., San Millan, J.L., Sancho, J., Avila, S., Escobar-Morreale, H.F., A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85 (2000), 2434–2438.
61. 61 Kumarapeli, V., Seneviratne Rde, A., Wijeyaratne, C.N., Yapa, R.M., Dodampahala, S.H., A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semi-urban population in Sri Lanka. Am J Epidemiol 168 (2008), 321–328.
62. 62 Michelmore, K.F., Balen, A.H., Dunger, D.B., Vessey, M.P., Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) 51 (1999), 779–786.
63. 63 Goodarzi, M.O., Quinones, M.J., Azziz, R., Rotter, J.I., Hsueh, W.A., Yang, H., Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. Fertil Steril 84 (2005), 766–769.
64. 64 Sirmans, S.M., Parish, R.C., Blake, S., Wang, X., Epidemiology and comorbidities of polycystic ovary syndrome in an indigent population. J Investig Med 62 (2014), 868–874.
65. 65 Tehrani, F.R., Simbar, M., Tohidi, M., Hosseinpanah, F., Azizi, F., The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reprod Biol Endocrinol, 9, 2011, 39.
66. 66 Dewailly, D., Lujan, M.E., Carmina, E., Cedars, M.I., Laven, J., Norman, R.J., et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 20 (2014), 334–352.
67. 67 Azziz, R., Dumesic, D.A., Goodarzi, M.O., Polycystic ovary syndrome: an ancient disorder?. Fertil Steril 95 (2011), 1544–1548.
68. 68 Baldani, D.P., Skrgatic, L., Simunic, V., Zlopasa, G., Canic, T., Trgovcic, I., Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in the Croatian population. Coll Antropol 37 (2013), 477–482.
69. 69 Belosi, C., Selvaggi, L., Apa, R., Guido, M., Romualdi, D., Fulghesu, A.M., et al. Is the PCOS diagnosis solved by ESHRE/ASRM 2003 consensus or could it include ultrasound examination of the ovarian stroma?. Hum Reprod 21 (2006), 3108–3115.
70. 70 Cupisti, S., Haeberle, L., Schell, C., Richter, H., Schulze, C., Hildebrandt, T., et al. The different phenotypes of polycystic ovary syndrome: no advantages for identifying women with aggravated insulin resistance or impaired lipids. Exp Clin Endocrinol Diabetes 119 (2011), 502–508.
71. 71 Dewailly, D., Catteau-Jonard, S., Reyss, A.C., Leroy, M., Pigny, P., Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol Metab 91 (2006), 3922–3927.
72. 72 Mehrabian, F., Khani, B., Kelishadi, R., Kermani, N., The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females. J Res Med Sci 16 (2011), 763–769.
73. 73 Hsu, M.I., Liou, T.H., Chou, S.Y., Chang, C.Y., Hsu, C.S., Diagnostic criteria for polycystic ovary syndrome in Taiwanese Chinese women: comparison between Rotterdam 2003 and NIH 1990. Fertil Steril 88 (2007), 727–729.
74. 74 Shroff, R., Syrop, C.H., Davis, W., Van Voorhis, B.J., Dokras, A., Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril 88 (2007), 1389–1395.
75. 75 Melo, A.S., Vieira, C.S., Romano, L.G., Ferriani, R.A., Navarro, P.A., The frequency of metabolic syndrome is higher among PCOS Brazilian women with menstrual irregularity plus hyperandrogenism. Reprod Sci 18 (2011), 1230–1236.
76. 76 Ehrmann, D.A., Liljenquist, D.R., Kasza, K., Azziz, R., Legro, R.S., Ghazzi, M.N., et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006), 48–53.
77. 77 Brower, M., Brennan, K., Pall, M., Azziz, R., The severity of menstrual dysfunction as a predictor of insulin resistance in PCOS. J Clin Endocrinol Metab 98 (2013), E1967–E1971.
78. 78 Legro, R.S., Chiu, P., Kunselman, A.R., Bentley, C.M., Dodson, W.C., Dunaif, A., Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype. J Clin Endocrinol Metab 90 (2005), 2571–2579.
79. 79 Kim, J.J., Hwang, K.R., Choi, Y.M., Moon, S.Y., Chae, S.J., Park, C.W., et al. Complete phenotypic and metabolic profiles of a large consecutive cohort of untreated Korean women with polycystic ovary syndrome. Fertil Steril 101 (2014), 1424–1430.
80. 80 Welt, C.K., Gudmundsson, J.A., Arason, G., Adams, J., Palsdottir, H., Gudlaugsdottir, G., et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab 91 (2006), 4842–4848.
81. 81 Diamanti-Kandarakis, E., Panidis, D., Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol (Oxf) 67 (2007), 735–742.
82. 82 Moran, L., Teede, H., Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 15 (2009), 477–488.
83. 83 Goverde, A.J., van Koert, A.J., Eijkemans, M.J., Knauff, E.A., Westerveld, H.E., Fauser, B.C., et al. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod 24 (2009), 710–717.
84. 84 Jones, H., Sprung, V.S., Pugh, C.J., Daousi, C., Irwin, A., Aziz, N., et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab 97 (2012), 3709–3716.
85. 85 Sahmay, S., Atakul, N., Oncul, M., Tuten, A., Aydogan, B., Seyisoglu, H., Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 170 (2013), 157–161.
86. 86 Romualdi, D., Di Florio, C., Tagliaferri, V., De Cicco, S., Gagliano, D., Immediata, V., et al. The role of anti-mullerian hormone in the characterization of the different polycystic ovary syndrome phenotypes. Reprod Sci 23 (2016), 655–661.
87. 87 Jamil, A.S., Alalaf, S.K., Al-Tawil, N.G., Al-Shawaf, T., Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Arch Gynecol Obstet 293 (2016), 447–456.
88. 88 Panidis, D., Tziomalos, K., Papadakis, E., Chatzis, P., Kandaraki, E.A., Tsourdi, E.A., et al. Associations of menstrual cycle irregularities with age, obesity and phenotype in patients with polycystic ovary syndrome. Hormones (Athens) 14 (2015), 431–437.
89. 89 Rizzo, M., Berneis, K., Hersberger, M., Pepe, I., Di Fede, G., Rini, G.B., et al. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod 24 (2009), 2286–2292.
90. 90 Guastella, E., Longo, R.A., Carmina, E., Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril 94 (2010), 2197–2201.
91. 91 Di Fede, G., Mansueto, P., Longo, R.A., Rini, G., Carmina, E., Influence of sociocultural factors on the ovulatory status of polycystic ovary syndrome. Fertil Steril 91 (2009), 1853–1856.
92. 92 Chae, S.J., Kim, J.J., Choi, Y.M., Hwang, K.R., Jee, B.C., Ku, S.Y., et al. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women. Hum Reprod 23 (2008), 1924–1931.
93. 93 Yilmaz, M., Isaoglu, U., Delibas, I.B., Kadanali, S., Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. J Obstet Gynaecol Res 37 (2011), 1020–1026.
94. 94 Panidis, D., Tziomalos, K., Misichronis, G., Papadakis, E., Betsas, G., Katsikis, I., et al. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod 27 (2012), 541–549.
95. 95 Wijeyaratne, C.N., Seneviratne Rde, A., Dahanayake, S., Kumarapeli, V., Palipane, E., Kuruppu, N., et al. Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic. Hum Reprod 26 (2011), 202–213.
96. 96 Ates, S., Sevket, O., Sudolmus, S., Dane, B., Ozkal, F., Uysal, O., et al. Different phenotypes of polycystic ovary syndrome in Turkish women: clinical and endocrine characteristics. Gynecol Endocrinol 29 (2013), 931–935.
97. 97 Guo, M., Chen, Z.J., Macklon, N.S., Shi, Y.H., Westerveld, H.E., Eijkemans, M.J., et al. Cardiovascular and metabolic characteristics of infertile Chinese women with PCOS diagnosed according to the Rotterdam consensus criteria. Reprod Biomed Online 21 (2010), 572–580.
98. 98 Wild, R.A., Carmina, E., Diamanti-Kandarakis, E., Dokras, A., Escobar-Morreale, H.F., Futterweit, W., et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 95 (2010), 2038–2049.
99. 99 Ezeh, U., Yildiz, B.O., Azziz, R., Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. J Clin Endocrinol Metab 98 (2013), E1088–E1096.
100. 100 Luque-Ramirez, M., Alpanes, M., Sanchon, R., Fernandez-Duran, E., Ortiz-Flores, A.E., Escobar-Morreale, H.F., Referral bias in female functional hyperandrogenism and polycystic ovary syndrome. Eur J Endocrinol 173 (2015), 603–610.
101. 101 Woodfine, J.D., Redelmeier, D.A., Berkson's paradox in medical care. J Intern Med 278 (2015), 424–426.